Subconjunctivally applied naïve Tregs support corneal graft survival in baby rats

Purpose Corneal transplantation is the most frequent and successful form of tissue transplantation in adults (<10% rejection). In young children, any corneal opacity should be corrected as early as possible to prevent lifelong visual impairment. However, the corneal graft rejection rate is dramatically increased in infants younger than 12 months of age (up to 85% rejection), and immunosuppressive therapy is particularly challenging in this age group. Regulatory T cells (Tregs) are a well-characterized T cell subpopulation with the potential to prevent autoimmune disorders or transplant rejection. Antigen-specific Tregs were shown to inhibit graft rejection in adult stem cell transplantation. Less is known about the role of naïve Tregs.The purpose of the present study was to elucidate the relevance of naïve Tregs in juvenile corneal transplantation in a baby rat keratoplasty model that reproduces the accelerated rejection in young patients. Methods Counts and inhibitory potential of Tregs were studied in spleens of 3- and 10-week-old rats. Unprimed Tregs (CD4+CD25+) were isolated from the spleens of 10-week-old Lewis rats and systemically or subconjunctivally administered in vivo in allogenic keratoplasty in 3- and 10-week-old Lewis recipient rats. In subconjunctival tissue, transcription was analyzed for induction of transforming-growth-factor beta (TGF-β). Results In 3-week-old rats, CD4 T cell counts, but not FoxP3 T cell counts were lower than in 10-week-old rats. The Tregs of both age groups had the potential to inhibit T cell activation in vitro. No significant delay in rejection was observed when Tregs were applied systemically before keratoplasty. However, subconjunctival application of Tregs abrogated rejection in 66.7% and 33.3% of the 3- and 10-week-old recipients, respectively. Analysis of the conjunctival tissue revealed a transplantation-induced increase in TGF-β transcription in the 3-week-old rats. Conclusions Our data suggest that local application of unprimed regulatory T cells may be a therapeutic strategy for preventing corneal graft rejection in young recipients.

[1]  R. Lechler,et al.  Promoting transplantation tolerance; adoptive regulatory T cell therapy , 2013, Clinical and experimental immunology.

[2]  R. Lee,et al.  Current trends in immunosuppressive therapies for renal transplant recipients. , 2012, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[3]  H. Zeng,et al.  In vitro-expanded CD4(+)CD25(high)Foxp3(+) regulatory T cells controls corneal allograft rejection. , 2012, Human immunology.

[4]  S. Sumitomo,et al.  Roles of LAG3 and EGR2 in regulatory T cells , 2012, Annals of the rheumatic diseases.

[5]  E. Molto,et al.  Assessment of immunological markers as mediators of graft vasculopathy development in heart transplantation. , 2011, Transplantation proceedings.

[6]  C. Anasetti,et al.  Efficient and selective prevention of GVHD by antigen-specific induced Tregs via linked-suppression in mice. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  J. Wagner,et al.  Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. , 2011, Blood.

[8]  M. Azuma,et al.  GITR ligand-mediated local expansion of regulatory T cells and immune privilege of corneal allografts. , 2010, Investigative ophthalmology & visual science.

[9]  J. Schwartzkopff,et al.  NK cell depletion delays corneal allograft rejection in baby rats , 2010, Molecular vision.

[10]  J. Myśliwska,et al.  First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells. , 2009, Clinical immunology.

[11]  R. Lechler,et al.  Indefinite mouse heart allograft survival in recipient treated with CD4(+)CD25(+) regulatory T cells with indirect allospecificity and short term immunosuppression. , 2009, Transplant immunology.

[12]  J. Schwartzkopff,et al.  Accelerated corneal graft rejection in baby rats , 2009, British Journal of Ophthalmology.

[13]  M. Haniffa,et al.  Regulatory T-Cell Suppression of CD8+ T-Cell-Mediated Graft-Versus-Host Reaction Requires Their Presence During Priming , 2009, Transplantation.

[14]  M. A. Curotto de Lafaille,et al.  Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? , 2009, Immunity.

[15]  J. Myśliwska,et al.  Ex vivo expansion of CD4+CD25+ T regulatory cells for immunosuppressive therapy , 2009, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[16]  R. Dana,et al.  Levels of Foxp3 in Regulatory T Cells Reflect Their Functional Status in Transplantation1 , 2009, The Journal of Immunology.

[17]  K. Ozawa,et al.  Development of new inbred transgenic strains of rats with LacZ or GFP. , 2005, Biochemical and biophysical research communications.

[18]  Matthias Edinger,et al.  Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. , 2005, Blood.

[19]  Peter R. Galle,et al.  Cutting Edge: TGF-β Induces a Regulatory Phenotype in CD4+CD25− T Cells through Foxp3 Induction and Down-Regulation of Smad7 , 2004, The Journal of Immunology.

[20]  F. Claas,et al.  Differential contribution of natural killer cells to corneal graft rejection in 3-week-old versus mature rats1 , 2003, Transplantation.

[21]  S. Wahl,et al.  TGF-β: the missing link in CD4+CD25+ regulatory T cell-mediated immunosuppression , 2003 .

[22]  T. Nomura,et al.  Control of Regulatory T Cell Development by the Transcription Factor Foxp3 , 2002 .

[23]  E. Godehardt,et al.  Synergism of RAD and Cyclosporin A in Prevention of Acute Rat Corneal Allograft Rejection , 2002, Cornea.

[24]  F. Powrie,et al.  Control of intestinal inflammation by regulatory T cells. , 2001, Microbes and infection.

[25]  Sayuri Yamazaki,et al.  Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance , 2001, Immunological reviews.

[26]  Ethan M. Shevach,et al.  CD4+CD25+ Immunoregulatory T Cells Suppress Polyclonal T Cell Activation In Vitro by Inhibiting Interleukin 2 Production , 1998, The Journal of experimental medicine.

[27]  E. Godehardt,et al.  Effect of mycophenolate mofetil, cyclosporin A, and both in combination in a murine corneal graft rejection model , 1998, The British journal of ophthalmology.

[28]  M. Toda,et al.  Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. , 1995, Journal of immunology.

[29]  R. Marks,et al.  Graft survival in four common groups of patients undergoing penetrating keratoplasty. , 1991, Ophthalmology.

[30]  J. McCulley,et al.  Ocular disease induced in mice by anterior chamber inoculation of herpes simplex virus. , 1984, Investigative ophthalmology & visual science.

[31]  C. Hsieh,et al.  Thymic and peripheral differentiation of regulatory T cells. , 2011, Advances in immunology.

[32]  M. Edinger,et al.  CD4+CD25+ regulatory T cells in hematopoietic stem cell transplantation. , 2005, Current topics in microbiology and immunology.

[33]  S. Wahl,et al.  TGF-beta: the missing link in CD4+CD25+ regulatory T cell-mediated immunosuppression. , 2003, Cytokine & growth factor reviews.

[34]  S. Hori,et al.  Control of autoimmunity by naturally arising regulatory CD4+ T cells. , 2003, Advances in immunology.

[35]  R. Zinkernagel,et al.  The discovery of MHC restriction. , 1997, Immunology today.

[36]  R. Sundmacher,et al.  Keratoplasty in newborns with Peters' anomaly. , 1996, German journal of ophthalmology.

[37]  H. Weiner,et al.  [Immunologic suppression of experimental autoimmune uveitis]. , 1991, Fortschritte der Ophthalmologie : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft.